Serrapeptase vs Telmisartan
A side-by-side research comparison of Serrapeptase and Telmisartan across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Serrapeptase | Telmisartan |
|---|---|---|
| Full name | Serrapeptase (Serratiopeptidase) | Telmisartan (ARB / Partial PPAR-gamma Agonist) |
| Category | Cardiovascular | Cardiovascular |
| Status | Dietary supplement | FDA-approved drug |
| Mechanism | Degrades non-living tissue including fibrin, blood clots, mucus, and arterial plaque without harming living cells. Inhibits bradykinin release and reduces prostaglandin synthesis for anti-inflammatory effects. | Blocks the angiotensin II type 1 (AT1) receptor to lower blood pressure and reduce vascular inflammation, while also acting as a partial PPAR-gamma agonist that improves insulin sensitivity, lipid handling, and mitochondrial biogenesis. |
| Molecular weight | ~52,000 Da | 514.62 Da |
| Half-life | ~4-6 hours | ~24 hours |
| Bioavailability | Oral (enteric-coated required); detectable in bloodstream | ~42-58% oral |
| Typical dose | 120,000-240,000 SPU | 20-80 mg per day |
| Frequency | Daily on empty stomach | Once daily |
| Route | Oral (enteric-coated) | Oral tablet |
Serrapeptase reported benefits
- Reduced inflammation and swelling
- Arterial plaque modulation
- Mucus/biofilm breakdown
- Post-surgical recovery
- Sinus/respiratory clearing
- Pain reduction
Telmisartan reported benefits
- Blood pressure control
- PPAR-gamma metabolic benefits
- Improved insulin sensitivity
- Vascular anti-inflammatory effects
- Cardio- and reno-protection
- 24-hour coverage
Related comparisons
Research and educational reference only. Not medical advice.